Chronic inflammation has been associated with a variety of human cancers. Although all surgical prostate specimens contain evidence of inflammation, the causal relationship between inflammation and prostate cancer has not been established. Interleulin-17 (IL-17) has been well accepted as a critical cytokine in inflammation. Both TH17 cells (T helper cells secreting IL-17) and IL-17 cytokine are increased in prostate cancer specimens, and the IL-17 receptors, IL-17RA and IL-17RC, are expressed in prostate cancer cells. However, the fundamental question of whether IL-17 plays an active role in prostate cancer needs to be determined. Our preliminary experiments revealed that in a mouse model of prostate cancer caused by conditionally mutant for Pten in the prostatic epithelium, IL- 17RC deficient (IL-17RC-) mice displayed smaller prostates and developed a reduced number of invasive prostate cancers with decreased inflammatory infiltration, reduced cellular proliferation, and increased apoptosis, compared to mice that express IL-17RC. Further, the fibromuscular stroma surrounding the prostatic glands was significantly thicker in IL-17RC- mice, a finding that we have associated with a decreased expression of matrix metalloproteinase 7 (MMP7). Addition of a recombinant mouse IL-17 induced the expression of MMP7 in the mouse prostate. Based on these findings, we have formulated a central hypothesis that, in prostate carcinogenesis caused by a Pten mutation, IL-17 facilitates prostate cancer formation and growth through an MMP7-mediated mechanism. This concept has clinical significance because blocking IL-17 or its downstream effectors such as MMP7 has the potential to be developed into new therapeutics in the prevention and treatment of prostate cancer;further, assessing the expression of IL-17- MMP7 signaling axis can be utilized as a prognostic indicator of prostate cancer. We propose to test our central hypothesis through the following three specific aims:
Aim 1 : Does MMP7 mediate IL-17's function in facilitating prostate cancer formation and growth in Pten- null mice? Aim 2: Assess the efficacy of targeting IL-17-MMP7 axis in preventing prostate cancer formation and growth in Pten-null mice.
Aim 3 : Determine the association between the IL-17-MMP7 axis and progression of human prostate cancer. Successful completion of the proposed studies will provide new insights into the molecular mechanisms underlying IL-17-mediated prostate carcinogenesis. Further, if any or all of the tested agents show efficacy, they can potentially be developed into preventive and/or therapeutic drugs against prostate cancer and other cancer types where IL-17 plays a role. The IL-17-MMP7 axis can potentially be utilized as new biomarkers in the prognosis of prostate cancer and in distinguishing between aggressive and indolent prostate cancers.

Public Health Relevance

The goals of this project are to determine the mechanisms of how a proinflammatory cytokine IL-17 facilitates formation and growth of prostate cancer, to assess if blocking IL-17's functions can prevent prostate cancer formation and growth, and to test if IL-17-associated molecules can be used as biomarkers to predict the prognosis of prostate cancer patients. The findings from this project will have significant potentials to be translated into prevention and treatment of human prostate cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA174714-01
Application #
8475822
Study Section
Molecular Oncogenesis Study Section (MONC)
Program Officer
Welch, Anthony R
Project Start
2013-07-01
Project End
2018-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
1
Fiscal Year
2013
Total Cost
$312,288
Indirect Cost
$104,788
Name
Tulane University
Department
Biology
Type
Schools of Medicine
DUNS #
053785812
City
New Orleans
State
LA
Country
United States
Zip Code
70118
Ge, Dongxia; Zhang, Qing-Song; Zabaleta, Jovanny et al. (2014) Doublecortin may play a role in defining chondrocyte phenotype. Int J Mol Sci 15:6941-60
Zhang, Qiuyang; Liu, Sen; Zhang, Qingsong et al. (2014) Interleukin-17 promotes development of castration-resistant prostate cancer potentially through creating an immunotolerant and pro-angiogenic tumor microenvironment. Prostate 74:869-79
Xu, Beibei; Guenther, James F; Pociask, Derek A et al. (2014) Promotion of lung tumor growth by interleukin-17. Am J Physiol Lung Cell Mol Physiol 307:L497-508
Li, Qingli; Liu, Lunxu; Zhang, Qiuyang et al. (2014) Interleukin-17 Indirectly Promotes M2 Macrophage Differentiation through Stimulation of COX-2/PGE2 Pathway in the Cancer Cells. Cancer Res Treat 46:297-306
Ren, Fuqiang; Fan, Mingyu; Mei, Jiandong et al. (2014) Interferon-? and celecoxib inhibit lung-tumor growth through modulating M2/M1 macrophage ratio in the tumor microenvironment. Drug Des Devel Ther 8:1527-38
Chen, Chong; Zhang, Qiuyang; Liu, Sen et al. (2014) AZD5363 Inhibits Inflammatory Synergy between Interleukin-17 and Insulin/Insulin-Like Growth Factor 1. Front Oncol 4:343
Lambrechts, Mark; Nazari, Behrooz; Dini, Arash et al. (2014) Comparison of the cheese-wiring effects among three sutures used in rotator cuff repair. Int J Shoulder Surg 8:81-5
Li, Qingli; Lambrechts, Mark J; Zhang, Qiuyang et al. (2013) Glyphosate and AMPA inhibit cancer cell growth through inhibiting intracellular glycine synthesis. Drug Des Devel Ther 7:635-43
Ge, Dongxia; Dauchy, Robert T; Liu, Sen et al. (2013) Insulin and IGF1 enhance IL-17-induced chemokine expression through a GSK3B-dependent mechanism: a new target for melatonin's anti-inflammatory action. J Pineal Res 55:377-87